Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP1 | O94782 | 7/20 | 0.39 |
| ▸ | WDR48 | Q8TAF3 | 7/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.37 |
| ▸ | TCF7L2 | Q9NQB0 | 3/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.35 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.34 |
| ▸ | LATS1 | O95835 | 2/20 | 0.34 |
| ▸ | LATS2 | Q9NRM7 | 2/20 | 0.34 |
| ▸ | PGK1 | P00558 | 1/20 | 0.34 |
| ▸ | C1R | P00736 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16666998 | 0.86 | DDR1 (0.36) | CTNNB1TCF7L2KDM1ADDR1C1R | |
| SCHEMBL16885094 | 0.85 | CTNNB1 (0.39) | CTNNB1TCF7L2HMOX1LATS1LATS2 | |
| SCHEMBL16666999 | 0.82 | DDR1 (0.42) | USP1WDR48CTNNB1TCF7L2KDM1A | |
| SCHEMBL1458846 | 0.82 | KDM1A (0.49) | USP1WDR48CTNNB1TCF7L2KDM1A | |
| SCHEMBL16872721 | 0.80 | TLR7 (0.46) | USP1WDR48LATS1LATS2 | |
| SCHEMBL19525347 | 0.79 | NLRP3 (0.36) | USP1WDR48KDM1ADDR1 | |
| SCHEMBL1458504 | 0.77 | LATS1 (0.53) | USP1WDR48KDM1ALATS1LATS2 | |
| SCHEMBL1459549 | 0.76 | PDE2A (0.44) | KDM1ATRPA1PGK1C1R | |
| SCHEMBL16872712 | 0.75 | DDR1 (0.37) | USP1WDR48DDR1C1R | |
| SCHEMBL16666218 | 0.74 | PTGES (0.51) | DDR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2865671-B1 | FUSED HETEROCYCLIC COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2017-11-01 | — | — | EP | disclosed |
| US-9328121-B1 | Fused heterocyclic compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-05-03 | — | — | US | disclosed |
| US-9328121-B1 | Fused heterocyclic compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-05-03 | — | — | US | disclosed |
| US-20160102100-A1 | FUSED HETEROCYCLIC COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2016-04-14 | — | — | US | disclosed |
| US-20160102100-A1 | FUSED HETEROCYCLIC COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2016-04-14 | — | — | US | disclosed |
| US-9260436-B2 | Fused heterocyclic compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-02-16 | — | — | US | disclosed |
| US-9260436-B2 | Fused heterocyclic compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-02-16 | — | — | US | disclosed |
| US-20150191474-A1 | FUSED HETEROCYCLIC COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-07-09 | — | — | US | disclosed |
| US-20150191474-A1 | FUSED HETEROCYCLIC COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-07-09 | — | — | US | disclosed |
| EP-2865671-A1 | FUSED HETEROCYCLIC COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2015-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102100-A1 | FUSED HETEROCYCLIC COMPOUND | NR4A1, CYP4B1, NR1H4 | USP1 2651/4885WDR48 2047/4885CTNNB1 2033/4885 |
| US-20150191474-A1 | FUSED HETEROCYCLIC COMPOUND | NR4A1, NR0B1, NR0B2 | USP1 2314/4885WDR48 1324/4885CTNNB1 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.